FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
Go back to FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)| Merck & Co. (NYSE: MRK) | Delayed: 152.34 +0.70 (0.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.64 | 52 Week High | $65.46 | |||
| Open | $152.80 | 52 Week Low | $47.97 | |||
| Day High | $152.80 | P/E | 103.63 | |||
| Day Low | $148.90 | EPS | $1.47 | |||
| Volume | 6,542,573 | |||||
